EUVIMEDEUVIMED entdecken
Multizentrische Studie

Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network

Maria T DeSancho, Erin Suvar, Jonathan C Roberts, Michael D Tarantino, Jonathan Schwartz, Jessica Callis, Michael Recht

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2024.07.026 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Maria T DeSancho und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York, USA. Electronic a…. Hauptthemen laut MEDLINE: Registries, Anticoagulants, Venous Thromboembolism, Antithrombin III Deficiency. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Grifols International.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with hereditary antithrombin deficiency (HAD) have an increased risk of venous thromboembolism (VTE). The American Thrombosis and Hemostasis Network (ATHN) 12: HAD Pilot Project established a registry to collect data on patients with HAD. OBJECTIVES: To inform current practice and serve as a platform to design a multicenter global registry for patients with HAD. METHODS: The HAD registry was designed in 2020 to identify 100 patients with HAD receiving care at ATHN-affiliated centers. Demographics, type of HAD, thrombotic events, risk factors, anticoagulants, and antithrombin (AT) concentrate administration were recorded. RESULTS: Ninety-four patients were included; 65% were females; 51% had type 1 HAD. Mean age at diagnosis was 26 years (SD, 18 years); 61% had VTE: 55% deep vein thrombosis and 27% pulmonary embolisms. Eight patients had arterial thrombosis. Recurrent thrombosis occurred in 58.6% of patients (44.8%) despite anticoagulation. The main risk factor for thrombosis in females was estrogen. Direct oral anticoagulants were prescribed in 30%, heparin in 34%, and warfarin in 32%. There were 139 pregnancies. Low-molecular-weight heparin was administered in 33% and AT concentrate in 19% and 11% prior to and after delivery, respectively. Twelve patients developed thrombosis in pregnancy. Seventy-nine patients underwent 239 surgeries or procedures, mainly gastrointestinal and vascular. Overall, 35% of participants received AT concentrate without adverse events. CONCLUSION: In ATHN 12, VTE was the predominant manifestation, frequently recurrent. There was a trend toward using direct oral anticoagulants. Low-molecular-weight heparin was administered in one-third of pregnancies and AT concentrate in one-fifth without adverse events. These data should encourage prospective studies to optimize the management of these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RegistriesAnticoagulantsVenous ThromboembolismAntithrombin III DeficiencyHumansPilot ProjectsFemaleMaleAdultRisk FactorsYoung AdultAdolescentMiddle AgedPregnancyUnited StatesChildAntithrombinsHemostasisRecurrenceVenous ThrombosisPulmonary Embolism

Stichwörter der Autor:innen

anticoagulantshereditary antithrombin deficiencypregnancyrisk factorsthrombosis

Substanzen

AnticoagulantsAntithrombins

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York, USA. Electronic address: mtd2002@med.cornell.edu.
  • Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York, USA.
  • Bleeding & Clotting Disorders Institute, Dills Family Foundation Center for Research at BCDI, Peoria, Illinois, USA; Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria,…
  • American Thrombosis and Hemostasis Network, Cornwall, New York, USA.
  • Department of Pediatric Hematology & Oncology, Yale University School of Medicine, New Haven, Connecticut, USA; National Bleeding Disorders Foundation, New York, New York, USA.

Förderung

  • Grifols International

Zitieren

APA

DeSancho, M. T., Suvar, E., Roberts, J. C., Tarantino, M. D., Schwartz, J., Callis, J., & Recht, M. (2024). Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.07.026

Vancouver

DeSancho MT, Suvar E, Roberts JC, Tarantino MD, Schwartz J, Callis J, et al. Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.07.026

BibTeX
@article{DeSancho2024,
  author = {DeSancho, Maria T and Suvar, Erin and Roberts, Jonathan C and Tarantino, Michael D and Schwartz, Jonathan and Callis, Jessica and Recht, Michael},
  title = {Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2024.07.026}
}
Kostenlos starten →